Basecamp Research completed an oversubscribed $140 million Series C financing to advance EDEN foundation models for AI-designed in vivo cell therapies. The company plans to train next-generation EDEN models and apply them to develop therapies across cancer and autoimmune disease. Basecamp’s approach centers on designing long, complex DNA sequences with large serine recombinases intended for precise delivery and to address manufacturing cost and complexity barriers seen in current cell therapy modalities. With investors including Anthropic via its Anthology Fund, the financing signals continuing capital flows into foundation-model-driven therapeutics—now increasingly oriented toward system-level reprogramming inside the body.